摘要
目的探讨大剂量地塞米松(dexamethasone,DXM)联合重组人血小板生成素(recombinant human thrombopoietin,rh TPO)及环孢素(ciclosporin,Cs)治疗免疫性血小板减少症(immune thrombocytopenia,ITP)的疗效。方法将55例ITP患者随机分为2组,观察组使用DXM、rh TPO及Cs,对照组使用DXM、rh TPO,对比2组近期疗效、远期疗效及不良反应。结果 2组近期疗效差异无统计学意义,远期疗效观察组明显优于对照组(P<0.05);2组各有1例因DXM不良反应减量使用。结论对使用DXM和rh TPO近期疗效良好的ITP患者,加用Cs治疗后可提高远期疗效。
Objective To investigate the treatment efficacy of immune thrombocytopenia（ ITP） by high-dose dexamethasone combined with thrombopoietin and ciclosporin（ Cs）. Methods Fifty-five cases of immune thrombocytopenia patients were randomly divided into two groups,the observation group with dexamethasone,recombinant human thrombopoietin（ rh TPO） and Cs,and the control group with dexamethasone and rh TPO. The short-term effect,long-term efficacy and side effects between the two groups were compared. Results There were no significant differences in short-term effect,long-term efficacy in observation group was significantly better than that in the control group. One case in each group reduce the dosage of dexamethasone for side effects. Conclusion Addition of Cs in patients with ITP who have recent good effects after the use dexamethasone and rh TPO can improve the long-term effectiveness.
出处
《转化医学杂志》
2016年第5期279-282,297,共5页
Translational Medicine Journal
